Mode of Action of dual immunotherapy

Prof. Dr. Pierre Coulie Université Catholique de Louvain, Belgium

Prof. Coulie explains the key properties of T cells for cancer therapy, in particular, the role of CTLA-4 and PD-1 checkpoints on T cells. He discusses treatment duration and proposed mechanisms for irAEs.

Dual immunotherapy: Experience in RCC

Prof. Dr. James Larkin The Royal Marsden, UK

Prof. Larkin discusses a 82 year old female patient diagnosed with metastatic RCC. He discusses his approach to managing this patient, including efficacy parameters, as well as management of uveitis, polyarthralgia and diarrhea, which was experienced by this patient during treatment.

Dual immunotherapy: Experience in mNSCLC

Dr. Ingel Demedts AZ Delta, Roeselare-Menen-Torhout, Belgium

Dr. Demedts discusses a 70 year old male patient diagnosed with metastatic NSCLC. He discusses his approach to managing this patient, including efficacy parameters, as well as management of skin toxicities, which was experienced by this patient during treatment.

Meet-the-Expert:

Interactive Panel Discussion

Topics discussed by prof Coulie, prof Larkin and dr Demedts included rationale for adding chemotherapy to dual I-O as well as the type of chemotherapy, mechanism behind anti-CTLA4 safety profile and the dose-dependent relationship, management of irAEs and key recommendations for pulmonologists who are new to treating with anti-CTLA4 inhibition.